Literature DB >> 17825960

Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.

Nicola Ternette1, Bettina Tippler, Klaus Uberla, Thomas Grunwald.   

Abstract

Respiratory syncytial virus F-protein (RSV-F) is poorly expressed from DNA expression plasmids containing the wild type RSV-F open reading frame. By codon optimization, premature polyadenylation signals were deleted and a striking enhancement of RSV-F expression levels was achieved. Therefore, the immunogenicity and efficacy of wild type DNA vaccines were compared to codon optimized expression plasmids encoding full-length RSV-F or its ectodomain. Mice were immunized twice with the different DNA vaccines followed by an RSV challenge. Only codon optimized DNA vaccines and in particular the one encoding the ectodomain of RSV-F induced substantial antibody levels and reduced viral load 13-170-fold. Thus, codon optimization enhances the immunogenicity and efficacy of RSV encoding DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825960     DOI: 10.1016/j.vaccine.2007.07.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

2.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

3.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

4.  Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.

Authors:  Hye Suk Hwang; Young-Man Kwon; Jong Seok Lee; Si-Eun Yoo; Yu-Na Lee; Eun-Ju Ko; Min-Chul Kim; Min-Kyoung Cho; Young-Tae Lee; Yu-Jin Jung; Ji-Yun Lee; Jian-Dong Li; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

5.  A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.

Authors:  Julia Steitz; Peter G Barlow; Jaber Hossain; Eun Kim; Kaori Okada; Tom Kenniston; Sheri Rea; Ruben O Donis; Andrea Gambotto
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

6.  Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.

Authors:  Eun Kim; Kaori Okada; Judy A Beeler; Roberta L Crim; Pedro A Piedra; Brian E Gilbert; Andrea Gambotto
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

7.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

8.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

9.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.